Fosfomycin for the treatment of resistant gram-negative bacterial infections: Insights from the society of infectious diseases pharmacists

Pharmacotherapy

Volumn 34, Issue 8, 2014, Pages 845-857

  Reffert, Julia L ^a   Smith, Winter J ^b  

^a OU Medical System   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

carbapenemase; ESBL; fosfomycin; infection; Pseudomonas aeruginosa; resistant

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; FOSFOMYCIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTEREMIA; BONE INFECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CYSTIC FIBROSIS; CYSTITIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENDOCARDITIS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE INFECTION; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; LUNG ABSCESS; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLEURA EMPYEMA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; URINARY TRACT INFECTION; ANIMAL; DRUG APPROVAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MULTIDRUG RESISTANCE; UNITED STATES;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FOSFOMYCIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; UNITED STATES;

EID: 84905908242     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1434     Document Type: Review

References (74)

1. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
2. Savard P, Perl T,. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis 2012; 25: 371-7.
3. Nicasio A, Kuti J, Nicolau D,. The current state of multidrug-resistant gram-negative bacilli in North America: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2008; 28: 235-49.
4. Yigit H, Queenan A, Anderson G, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-61.
5. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR,. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155: 1699-704.
6. Rodriguez-Rojas A, Macia MD, Couce A, et al. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS ONE 2010; 5: e10193.
7. Raz R,. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect 2012; 18: 4-7.
8. Popovic M, Steinort D, Pillai S, Joukhadar C,. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2010; 29: 127-42.
9. Andrews JM, Baquero F, Beltran JM, et al. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother 1983; 12: 357-61.
10. Grimm H,. In vitro investigations with fosfomycin on Mueller-Hinton agar with and without glucose-6-phosphate. Infection 1979; 7: 256-9.
11. Forest Laboratories, Inc. Monurol (fosfomycin) package insert. St. Louis, MO: Forest Laboratories, Inc; 1997.
12. Pasteran F, Lucero C, Rapoport M, et al. Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae. J Infect Dev Ctries 2012; 6: 452-6.
13. Michalopoulos AS, Livaditis IG, Gougoutas V,. The revival of fosfomycin. Int J Infect Dis 2011; 15: e732-9.
14. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI,. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008; 46: 1069-77.
15. Gupta K, Hooton T, Naber K, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-20.
16. Anonymous. Addendum: cost of drugs for acute cystitis. Med Lett Drugs Ther 2012; 54: 67-8.
17. Kahan FM, Kahan JS, Cassidy PJ, Kropp H,. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974; 235: 364-86.
18. Pogue JM, Marchaim D, Kaye D, Kaye KS,. Revisiting "older" antimicrobials in the era of multidrug resistance. Pharmacotherapy 2011; 31: 912-21.
19. Garau J,. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008; 14 (Suppl 1): 198-202.
20. Butcu M, Akcay SS, Inan AS, Aksaray S, Engin DO, Calisici G,. In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics. J Infect Chemother 2011; 17: 575-8.
21. Heintz BH, Halilovic J, Christensen CL,. Vancomycin-resistant enterococcal urinary tract infections. Pharmacotherapy 2010; 30: 1136-49.
22. Miro JM, Entenza JM, Del Rio A, et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2012; 56: 4511-5.
23. Shrestha NK, Chua JD, Tuohy MJ, et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis 2003; 35: 12-4.
24. Tang HJ, Chen CC, Cheng KC, et al. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. J Antimicrob Chemother 2012; 67: 944-50.
25. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008; 27: 439-43.
26. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME,. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens. J Antimicrob Chemother 2012; 67: 255-68.
27. Rodriguez A, Gallego A, Olay T, Mata JM,. Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy 1977; 23 (Suppl 1): 247-58.
28. Oteo J, Bautista V, Lara N, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010; 65: 2459-63.
29. Oteo J, Orden B, Bautista V, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009; 64: 712-7.
30. Wilson DT, May DB,. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Am J Ther 2013; 20: 685-90.
31. Prakash V, Lewis JS 2nd, Herrera ML, Wickes BL, Jorgensen JH,. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2009; 53: 1278-80.
32. Demir T, Buyukguclu T,. Evaluation of the in vitro activity of fosfomycin tromethamine against gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis 2013; 17: e966-70.
33. Araj GF, Jaber FA,. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. J Med Liban 2012; 60: 142-7.
34. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE,. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50.
35. Tuon FF, Rocha JL, Formighieri MS, et al. Fosfomycin susceptibility of isolates with blaKPC-2 from Brazil. J Infect 2013; 67: 247-9.
36. Kopacz J, Mariano N, Colon-Urban R, et al. Identification of extended-spectrum-beta-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M beta-lactamases in nonhospitalized patients. Antimicrob Agents Chemother 2013; 57: 5166-9.
37. Pogue JM, Marchaim D, Abreu-Lanfranco O, et al. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. J Antibiot (Tokyo) 2013; 66: 625-7.
38. Endimiani A, Patel G, Hujer KM, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010; 54: 526-9.
39. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010; 50: 364-73.
40. Pano-Pardo JR, Ruiz-Carrascoso G, Navarro-San Francisco C, et al. Infections caused by OXA-48-producing Klebsiella pneumoniae in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak. J Antimicrob Chemother 2013; 68: 89-96.
41. Navarro-San Francisco C, Mora-Rillo M, Romero-Gomez MP, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect 2013; 19: E72-9.
42. Li JJ, Sheng ZK, Deng M, et al. Epidemic of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and 16S rRNA methylase RmtB in a Chinese university hospital. BMC Infect Dis 2012; 12: 373.
43. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N,. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-9.
44. Perry JD, Naqvi SH, Mirza IA, et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother 2011; 66: 2288-94.
45. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI,. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009; 34: 111-20.
46. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME,. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009; 34: 506-15.
47. Parker S, Lipman J, Koulenti D, Dimopoulos G, Roberts JA,. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 2013; 42: 289-93.
48. Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ,. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003; 2: 19-24.
49. Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A,. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-beta-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother 2013; 57: 1421-7.
50. McCaughey G, McKevitt M, Elborn JS, Tunney MM,. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros 2012; 11: 163-72.
51. Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME,. Synergy of fosfomycin with other antibiotics for gram-positive and gram-negative bacteria. Eur J Clin Pharmacol 2010; 66: 359-68.
52. Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME,. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012; 31: 695-701.
53. Souli M, Galani I, Boukovalas S, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011; 55: 2395-7.
54. Yamada S, Hyo Y, Ohmori S, Ohuchi M,. Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa. Chemotherapy 2007; 53: 202-9.
55. Santos DA, Nascimento MM, Vitali LH, Martinez R,. In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa. Rev Soc Bras Med Trop 2013; 46: 299-303.
56. Martinez-Martinez L, Rodriguez G, Pascual A, Suarez AI, Perea EJ,. In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1996; 38: 1107-8.
57. Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW,. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 2011; 42: 890-900.
58. Zhang Y, Chen F, Sun E, Ma R, Qu C, Ma L,. In vitro antibacterial activity of combinations of fosfomycin, minocycline and polymyxin B on pan-drug-resistant Acinetobacter baumannii. Exp Ther Med 2013; 5: 1737-9.
59. Mellon G, Clec'h C, Picard B, Cohen Y, Jaureguy F,. Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin. J Infect Chemother 2012; 18: 958-60.
60. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185: 171-8.
61. Pullukcu H, Tasbakan M, Sipahi O, Yamazhan T, Aydemir S, Ulusoy S,. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62-5.
62. Senol S, Tasbakan M, Pullukcu H, et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother 2010; 22: 355-7.
63. Rodriguez-Bano J, Alcala JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-902.
64. Neuner EA, Sekeres J, Hall GS, van Duin D,. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012; 56: 5744-8.
65. Dinh A, Salomon J, Bru JP, Bernard L,. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis 2012; 44: 182-9.
66. Peirano G, Ahmed-Bentley J, Woodford N, Pitout JD,. New Delhi metallo-beta-lactamase from traveler returning to Canada. Emerg Infect Dis 2011; 17: 242-4.
67. Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, Spyridopoulou K, Daikos GL,. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 2012; 67: 2777-9.
68. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME,. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16: 184-6.
69. Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria. Int J Antimicrob Agents 2014; 43: 52-9.
70. Apisarnthanarak A, Mundy LM,. Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia. Clin Infect Dis 2010; 51: 1352-4.
71. Mayama T, Yokota M, Shimatani I, Ohyagi H,. Analysis of oral fosfomycin calcium (Fosmicin) side-effects after marketing. Int J Clin Pharmacol Ther Toxicol 1993; 31: 77-82.
72. Qiao LD, Zheng B, Chen S, et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open 2013; 3: e004157.
73. Florent A, Chichmanian RM, Cua E, Pulcini C,. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents 2011; 37: 82-3.
74. Anonymous. Section 4.1: drug monographs. In: Clinical guidance on injectable drugs. Plymouth, UK: Derriford Hospital Pharmacy Department, 2010: 1-159.